Antibodies by design: from drug development to brain drug delivery

Add to your list(s) Download to your calendar using vCal

• Prof Peter M. Tessier, University of Michigan
• Monday 08 April 2024, 14:00-15:00
• Department of Chemistry, Cambridge, Wolfson Lecture Theatre.

If you have a question about this talk, please contact Echo Wu Williamson.

The biotech industry has seen an explosion in the development of therapeutic antibodies in the last two decades, and today most of the best-selling drugs are monoclonal antibodies. The advantages of antibodies as therapeutics – namely their high affinity, specificity, potency, stability, manufacturability, and low toxicity – are compelling. Nevertheless, there are many fundamental challenges associated with co-optimizing their key properties due to strong inherent tradeoffs, such as affinity/specificity, affinity/stability, and species cross-reactivity tradeoffs, which greatly impede their development. I will discuss our progress in addressing these challenges in a rational and predictive manner using machine learning, including several examples of multi-objective optimization ranging from antibody drug development to efficient and long-lived brain delivery of IgGs using bispecific antibodies.

This talk is part of the Biological Chemistry Research Interest Group series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biological Chemistry Research Interest Group
• Department of Chemistry
• Department of Chemistry, Cambridge, Wolfson Lecture Theatre
• Featured lists
• School of Physical Sciences

Note that ex-directory lists are not shown.